某院616例新型冠状病毒肺炎患者用药分析

Analysis of Drug Use in 616 Patients with Coronavirus Disease 2019 in a Hospital

目的为中西医结合治疗新型冠状病毒肺炎(COVID-19)提供参考。方法选取某中西医结合医院2020年1月8日至2月28日收治的重型COVID-19患者616例,收集患者的一般临床资料、用药情况,同时比较西药组(117例)和中西药组(499例)人口学特征、住院时间、疾病转归。结果 COVID-19药物治疗结构合理,无非必要辅助用药情况;以中西药结合治疗为主,一人一方使用比例达81. 01%(499/616);西药组和中西药组患者人口学特征无显著差异(P> 0. 05),但中西药组患者住院时间、危重型转化率及死亡率显著低于西药组(P <0. 05)。结论中西医结合治疗能缩短COVID-19患者住院时间,减少重型向危重型转化,降低患者死亡率。

Objective To provide reference for the treatment of coronavirus disease 2019( COVID-19) with the integrated traditional Chinese and Western medicine. Methods Totally 616 patients with severe COVID-19 admitted to a hospital of integrated Chinese and Western medicine from January 8 th,2020 to February 28 th,2020 were selected,the general clinical data and medication conditions of the patients were collected. At the same time,the demographic characteristics,hospitalization time and disease outcome of the Western medicine group( 117 cases) and the Chinese Western medicine group( 499 cases) were compared. Results The structure of drug treatment for COVID-19 was reasonable and there was no unnecessary auxiliary medication. Among them,the combination of Chinese and Western medicine was the main treatment method,and the proportion of one prescription for one person was 81. 01%( 499/616). There was no significant difference in demographic characteristics between the Western medicine group and the Chinese and Western medicine group( P > 0. 05),but the hospitalization time,the conversion rate to severe and the mortality rate in the Chinese and Western medicine group were significantly lower than those in the Western medicine group( P < 0. 05). Conclusion Integrated traditional Chinese and Western medicine can shorten the hospitalization time of patients with COVID-19,reduce the conversion rate from severe type to critical type,and reduce the mortality of patients.